Truist Financial Forecasts Strong Price Appreciation for Collegium Pharmaceutical (NASDAQ:COLL) Stock

Collegium Pharmaceutical (NASDAQ:COLL) had its target price lifted by equities researchers at Truist Financial from $45.00 to $48.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Truist Financial’s price objective suggests a potential upside of 13.48% from the stock’s current price.

A number of other equities analysts also recently commented on COLL. Needham & Company LLC reiterated a “buy” rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a research note on Tuesday, October 28th. Zacks Research downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 23rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Wednesday, October 8th. Wall Street Zen lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 18th. Finally, HC Wainwright raised their price objective on Collegium Pharmaceutical from $44.00 to $46.00 and gave the stock a “buy” rating in a research note on Friday. Three equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $44.25.

Collegium Pharmaceutical Stock Up 4.0%

COLL stock opened at $42.30 on Friday. Collegium Pharmaceutical has a twelve month low of $23.23 and a twelve month high of $43.06. The company has a current ratio of 1.54, a quick ratio of 1.10 and a debt-to-equity ratio of 2.94. The company has a market capitalization of $1.33 billion, a P/E ratio of 26.27 and a beta of 0.61. The firm has a 50 day simple moving average of $35.70 and a 200-day simple moving average of $32.80.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share (EPS) for the quarter. The firm had revenue of $135.55 million for the quarter. Collegium Pharmaceutical had a net margin of 7.72% and a return on equity of 102.03%. On average, equities research analysts predict that Collegium Pharmaceutical will post 5.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Thomas B. Smith sold 17,478 shares of the firm’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $38.42, for a total value of $671,504.76. Following the sale, the executive vice president owned 70,264 shares of the company’s stock, valued at approximately $2,699,542.88. This trade represents a 19.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Scott Dreyer sold 16,389 shares of the business’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $38.21, for a total value of $626,223.69. Following the transaction, the executive vice president owned 103,613 shares of the company’s stock, valued at $3,959,052.73. This represents a 13.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 74,133 shares of company stock valued at $2,899,504 over the last quarter. Company insiders own 2.51% of the company’s stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

Hedge funds and other institutional investors have recently modified their holdings of the company. Federated Hermes Inc. increased its holdings in shares of Collegium Pharmaceutical by 67.0% in the 3rd quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 350 shares during the period. CWM LLC grew its position in Collegium Pharmaceutical by 453.9% in the 2nd quarter. CWM LLC now owns 1,407 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 1,153 shares during the last quarter. Hantz Financial Services Inc. grew its position in Collegium Pharmaceutical by 137.7% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock worth $60,000 after purchasing an additional 993 shares during the last quarter. Wealthquest Corp acquired a new stake in shares of Collegium Pharmaceutical in the first quarter valued at approximately $62,000. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Collegium Pharmaceutical by 744.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after buying an additional 2,190 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.